Enhances hepatic insulin sensitivity\t\t \tStatin\tFor diabetic dyslipidemia\t\t\t \tAdiponectin\tDecreased adiponectin levels are thought to playa central role in the development of type 2 diabetes and obesity\tAdipoRon is a novel orally-active small molecule that serves as a potent selective agonist of the AdipoR1 and AdipoR2 adiponectin receptors\t\t \tGlut4\tTriggering the canonical PI3K-AKT pathway is essential and ample to activate exocytosis of GLUT4 storage vesicles to the plasma membrane\tStaurosporine is used to promotes GSVs translocation and glucose uptake through the AMPK pathwayRutamarin as a dual inducer of both GLUT4 translocation and expression efficiently ameliorates glucose homeostasis in insulin-resistant mice\t\t \tPGC-1alpha\tReduction in PGC-1alpha triggers insulin resistance and ultimately causes diabetes\tStill waiting to synthesize agonist\t\t \t", "sentences": [], "annotations": [], "relations": []}, {"offset": 53688, "infons": {"file": "biomedicines-10-00331-t004.xml", "id": "biomedicines-10-00331-t004", "section_type": "TABLE", "type": "table_caption"}, "text": "Diabetes Mellitus.", "sentences": [], "annotations": [], "relations": []}, {"offset": 53707, "infons": {"file": "biomedicines-10-00331-t004.xml", "id": "biomedicines-10-00331-t004", "section_type": "TABLE", "type": "table", "xml": "<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"center\" valign=\"middle\" style=\"border-top:solid thin;border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Trend Box</th></tr></thead><tbody><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Diabetes mellitus is a complex metabolic disruption characterized by chronic hyperglycemia due to deficiencies in insulin production, its systemic release and action, and resistance.</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Incident diabetes is also due to changes in performance of multiple key enzymes. Therefore, identifying and understanding key targets at structure-function-dynamics levels and their potential leads and/or drugs, shortcomings, and associated challenges all together can provide a roadmap for the discovery of new selective modulators.</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">We listed promising therapeutic targets for treatment of T2DM, most of them involving improvements in glucose tolerance. </td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Novel drugs from various targets have numerous locales of activity and each focus on a few components of the metabolic disorder. These may help pave the way for future type 2 diabetes treatments.</td></tr></tbody></table>\n"}, "text": "Trend Box\t \tDiabetes mellitus is a complex metabolic disruption characterized by chronic hyperglycemia due to deficiencies in insulin production, its systemic release and action, and resistance.\t \tIncident diabetes is also due to changes in performance of multiple key enzymes. Therefore, identifying and understanding key targets at structure-function-dynamics levels and their potential leads and/or drugs, shortcomings, and associated challenges all together can provide a roadmap for the discovery of new selective modulators.\t \tWe listed promising therapeutic targets for treatment of T2DM, most of them involving improvements in glucose tolerance. \t \tNovel drugs from various targets have numerous locales of activity and each focus on a few components of the metabolic disorder. These may help pave the way for future type 2 diabetes treatments.